KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $1.5 billion.

  • Vertex Pharmaceuticals' Short-term Investments fell 148.74% to $1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 billion, marking a year-over-year decrease of 148.74%. This contributed to the annual value of $1.5 billion for FY2025, which is 148.74% down from last year.
  • As of Q4 2025, Vertex Pharmaceuticals' Short-term Investments stood at $1.5 billion, which was down 148.74% from $1.3 billion recorded in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Short-term Investments peaked at $1.5 billion during Q4 2024, and registered a low of $274.5 million during Q4 2022.
  • Its 5-year average for Short-term Investments is $974.3 million, with a median of $931.2 million in 2023.
  • Its Short-term Investments has fluctuated over the past 5 years, first crashed by 6239.21% in 2022, then skyrocketed by 20936.25% in 2023.
  • Vertex Pharmaceuticals' Short-term Investments (Quarter) stood at $729.9 million in 2021, then plummeted by 62.39% to $274.5 million in 2022, then skyrocketed by 209.36% to $849.2 million in 2023, then soared by 82.09% to $1.5 billion in 2024, then fell by 1.49% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q4 2025, $1.3 billion for Q3 2025, and $1.4 billion during Q2 2025.